Intuitive Surgical, Inc.
Moat Score — Intuitive Surgical, Inc.
Total Moat Score
21 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Intuitive holds more than 5,600 granted/in-force patents and over 2,500 pending worldwide covering da Vinci system architecture, instruments, and procedure-specific technology, backed by 25 years of accumulated clinical evidence across 70+ representative uses that competitors like Medtronic's Hugo and J&J's Ottava are still working to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Intuitive's non-GAAP gross margin of 67.6% in FY2025 reflects a profitable, premium-priced model rather than a low-cost production advantage; its manufacturing is specialized and R&D-heavy, and well-capitalized rivals like Johnson & Johnson and Medtronic have comparable or greater manufacturing scale to draw on. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the entrenched standard-of-care platform with surgeons trained specifically on da Vinci, Intuitive has historically been able to sustain high margins on capital systems and consumable instruments; this is now being tested for the first time by credible competitors, but near-term pricing power remains strong given switching friction. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 2 / 5 | Value compounds somewhat as more surgeons are trained on da Vinci and more clinical outcomes data accumulates across the installed base, reinforcing the platform as the training and evidentiary standard, though this is an indirect, data/training network effect rather than a direct user-to-user network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 5 / 5 | Once a hospital buys a da Vinci system, trains and credentials its surgical staff, and builds OR workflows and instrument inventories around it, switching to a competing robotic platform means re-training surgeons, re-credentialing, and absorbing a new multi-million-dollar capital purchase — an extremely high, multi-year switching barrier reinforced across an 11,106-system installed base. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Robotic surgery platforms require enormous, multi-decade R&D and clinical-evidence investment to reach general-purpose, multi-specialty capability, which has kept the field to a small number of serious players; but the entry of Johnson & Johnson, Medtronic, and several Chinese competitors in the last few years shows the market can support more than one credible platform, so this is a meaningful but no longer absolute barrier. |